Table 2. PBN-derived ROS production under stimulation according to the phenotype of asthma.
| Stimulation | SA (n = 9) | NSA (n = 49) | P value* (SA vs. NSA) | Asthma (n = 58) | AERD (n = 20) | ATA (n = 38) | P value* (AERD vs. ATA) | |
|---|---|---|---|---|---|---|---|---|
| fMLP stimulation | ||||||||
| Con | 1,642.33 ± 1,673.77 | 1,292.9 ± 808.57 | 0.151 | 1,347.12 ± 979.81 | 2,031.85 ± 1,399.63 | 986.74 ± 293.6 | < 0.001 | |
| fMLP | 3,235.44 ± 2,868.46 | 2,059.61 ± 806.32 | 0.011 | 2,242.07 ± 1,373.59 | 3,073.9 ± 1,935.96 | 1,804.26 ± 641.18 | 0.001 | |
| fMLP + FTY | 2,491 ± 1,947.11 | 1,699.79 ± 681.63 | 0.030 | 1,824.72 ± 1,008.1 | 2,433.11 ± 1,430.3 | 1,520.53 ± 507.75 | 0.002 | |
| LPS stimulation | ||||||||
| Con | 1,642.33 ± 1,673.77 | 1,292.9 ± 808.57 | 0.151 | 1,347.12 ± 979.81 | 2,031.85 ± 1,399.63 | 986.74 ± 293.6 | < 0.001 | |
| LPS | 2,541.38 ± 2,262.17 | 1,758.19 ± 897.58 | 0.100 | 1,883.5 ± 1,220.37 | 2,800.07 ± 1,696.19 | 1,527.06 ± 741.39 | 0.002 | |
| LPS + FTY | 1,944.5 ± 1,969.66 | 1,498.95 ± 639.46 | 0.189 | 1,570.24 ± 961.04 | 2,329.07 ± 1,482.62 | 1,275.14 ± 395.82 | 0.001 | |
Data are presented as means ± standard deviation of the mean fluorescence intensity values.
SA, severe asthma; NSA, non-severe asthma; AERD, aspirin-exacerbated respiratory disease; ATA, aspirin-tolerant asthma; Con, mock-treated cells; fMLP, N-formyl-methionyl-leucyl-phenylalanine, LPS, lipopolysaccharide; FTY, FTY720.
*P value was calculated by general linear regression analysis. The values in bold indicate significant P values.